Current Pharmacology Reports

, Volume 6, Issue 1, pp 8–23 | Cite as

Neuropathology of Kynurenine Pathway of Tryptophan Metabolism

  • Abdulkarim Tutakhail
  • Lysiane Boulet
  • Sarah Khabil
  • Qand Agha Nazari
  • Hafiza Hamid
  • François CoudoréEmail author
Neuropharmacology (R Pi and G Aston-Jones, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Neuropharmacology
  2. Topical Collection on Neuropharmacology


The different branches of kynurenine pathways of tryptophan metabolism are the important mechanism to elucidate various neurological and immunological disorders. There is a substantial body of evidence indicating the involvement of kynurenine pathway (KP) in the pathophysiology of some neuropsychiatric and neurodegenerative perturbation. This pathway generates neuro-active compounds, those can interact with neurotransmitters receptors in the central nervous system (CNS). According to some recent studies, there are a strong relation between KP’s related enzymes such as indoleamine 2,3 dioxygenase (IDO) and tryptophan 2,3 dioxygenase (TDO) activation and neurological disease. In this review article, we focus on the level/ratios of different metabolites and precursors such as tryptophan (TRP), 5-hydroxytryptamine (5-HT), kynurenine (KYN), kynurenic acid (KYNA), and quinolinic acid (QUIN) in order to find the link with the KP-induced neuropathologies. Kynurenine metabolism is hypothesized to be one of the key mechanisms that link inflammation and depression. Some factors such as exercise (through PGC-1α), inflammation, stress, and some medication have the remarkable effects on KP. We highlight the role of different causes such as inflammation and stress, Tryptophan-kynurenine pathway with the whole biochemical and organ-specific biochemistry, and the neuropathomechanism of related pathologies. Here, we discuss the relations, the changes, and the mutual effects of KP with major depressive disorders, bipolar disorders, schizophrenia, Parkinson’s, and Alzheimer’s disease.


Kynurenine pathway KYNs Excitotoxicity Neuropsychiatric diseases Neurodegenerative diseases 



Kynurenine pathway




Kynurenic acid






Anthranilic acid


Xanthurenic acid


Tryptophan 2, 3 dioxygenase


Indoleamine 2, 3 dioxygenase


Kynurenine aminotransferase


Kynurenine monoxygenase


Nicotinamide adenine dinucleotide


Bile duct ligation


N-methyl D-aspartate




Tryptophan hydroxylase


5-hydroxyindoleacetic acid


Bipolar disorders


Huntington disease


Alzheimer’s disease


Parkinson’s disease


Major depressive disorders


Toll-like receptors


1-Methyl tryptophan


Brain-derived neurotrophic factor


Tropomycin receptor kinase B


Prefrontal cortex


Cornu ammonis of hippocampus


Multiple sclerosis


Fibronectin type III domain containing 5


Cerebrospinal fluid


Prepulse Inhibition




Picolinic acid


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights Informed Consent

This article does not contain any studies involving human or animal subjects performed by any of the authors.


  1. 1.
    Austin CJD, Rendina LM. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy. Drug Discov Today. 2015;20:609–17.PubMedGoogle Scholar
  2. 2.
    Opitz CA, Heiland I. Dynamics of NAD-metabolism: everything but constant. Biochem Soc Trans. 2015;43:1127–32.PubMedGoogle Scholar
  3. 3.
    Moyer BJ, Rojas IY, Murray IA, Lee S, Hazlett HF, Perdew GH, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor. Toxicol Appl Pharmacol. 2017;323:74–80.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Brandacher G, Hoeller E, Fuchs D, Weiss HG. Chronic immune activation underlies morbid obesity: is IDO a key player? Curr Drug Metab. 2007;8:289–95.PubMedGoogle Scholar
  5. 5.
    Sarkar SA, Wong R, Hackl SI, Moua O, Gill RG, Wiseman A, et al. Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets. Diabetes. 2007;56:72–9.PubMedGoogle Scholar
  6. 6.
    Chen W. IDO: more than an enzyme. Nat Immunol. 2011;12:809–11.PubMedGoogle Scholar
  7. 7.
    Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature. 2014;511:184–90.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Fujigaki H, Yamamoto Y, Saito K. L-tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: focus on cell type differences. Neuropharmacology. 2017;112:264–74.PubMedGoogle Scholar
  9. 9.
    Badawy AA-B. Tryptophan availability for kynurenine pathway metabolism across the life span: control mechanisms and focus on aging, exercise, diet and nutritional supplements. Neuropharmacology. 2017;112:248–63.PubMedGoogle Scholar
  10. 10.
    Oxenkrug G. Interferon-gamma - inducible inflammation: contribution to aging and aging-associated psychiatric disorders. Aging Dis. 2011;2:474–86.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry. 2010;15:393–403.Google Scholar
  12. 12.
    Baranyi A, Meinitzer A, Breitenecker RJ, Amouzadeh-Ghadikolai O, Stauber R, Rothenhäusler H-B. Quinolinic acid responses during interferon-α-induced depressive symptomatology in patients with chronic hepatitis C infection - a novel aspect for depression and inflammatory hypothesis. PLoS One. 2015;10:e0137022.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein H-G, Sarnyai Z, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation. 2011;8:94.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Myint A-M, Kim YK, Verkerk R, Scharpé S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007;98:143–51.PubMedGoogle Scholar
  15. 15.
    Schwieler L, Samuelsson M, Frye MA, Bhat M, Schuppe-Koistinen I, Jungholm O, et al. Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients. J Neuroinflammation. 2016;13:51.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Träskman-Bendz L, Guillemin GJ, et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav Immun. 2015;43:110–7.Google Scholar
  17. 17.
    Cho HJ, Savitz J, Dantzer R, Teague TK, Drevets WC, Irwin MR. Sleep disturbance and kynurenine metabolism in depression. J Psychosom Res. 2017;99:1–7.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Schwarcz R, Bruno JP, Muchowski PJ, Wu H-Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13:465–77.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Refaey ME, McGee-Lawrence ME, Fulzele S, Kennedy EJ, Bollag WB, Elsalanty M, et al. Kynurenine, a tryptophan metabolite that accumulates with age, induces bone loss. J Bone Miner Res Off J Am Soc Bone Miner Res. 2017;32:2182–93.Google Scholar
  20. 20.
    Matthews KA, Schott LL, Bromberger JT, Cyranowski JM, Everson-Rose SA, Sowers M. Are there bi-directional associations between depressive symptoms and C-reactive protein in mid-life women? Brain Behav Immun. 2010;24:96–101.PubMedGoogle Scholar
  21. 21.
    Prescott C, Weeks AM, Staley KJ, Partin KM. Kynurenic acid has a dual action on AMPA receptor responses. Neurosci Lett. 2006;402:108–12.PubMedGoogle Scholar
  22. 22.
    Moroni F, Cozzi A, Sili M, Mannaioni G. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm Vienna Austria 1996. 2012;119:133–9.PubMedGoogle Scholar
  23. 23.
    Jiang X, Xu L, Tang L, Liu F, Chen Z, Zhang J, et al. Role of the indoleamine-2,3-dioxygenase/kynurenine pathway of tryptophan metabolism in behavioral alterations in a hepatic encephalopathy rat model. J Neuroinflammation. 2018;15:3.PubMedPubMedCentralGoogle Scholar
  24. 24.
    O’Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, Lestage J, et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci. 2009;29:4200–9.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B, et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology. 2013;38:1609–16.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Heisler JM, O’Connor JC. Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism mediates inflammation-induced deficit in recognition memory. Brain Behav Immun. 2015;50:115–24.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Parrott JM, O’Connor JC. Kynurenine 3-monooxygenase: an influential mediator of neuropathology. Front Psychiatry. 2015;6:116.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Wejksza K, Rzeski W, Okuno E, Kandefer-Szerszen M, Albrecht J, Turski WA. Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in oligodendrocyte cell line (OLN-93). Neurochem Res. 2005;30:963–8.PubMedGoogle Scholar
  29. 29.
    Ramírez-Ortega D, Ramiro-Salazar A, González-Esquivel D, Ríos C, Pineda B, Pérez de la Cruz V. 3-Hydroxykynurenine and 3-hydroxyanthranilic acid enhance the toxicity induced by copper in rat astrocyte culture. Oxidative Med Cell Longev. 2017;2017:2371895.Google Scholar
  30. 30.
    Baran H, Staniek K, Bertignol-Spörr M, Attam M, Kronsteiner C, Kepplinger B. Effects of various kynurenine metabolites on respiratory parameters of rat brain, liver and heart mitochondria. Int J Tryptophan Res. 2016;9:17–29.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Vazquez S, Garner B, Sheil MM, Truscott RJ. Characterisation of the major autoxidation products of 3-hydroxykynurenine under physiological conditions. Free Radic Res. 2000;32:11–23.PubMedGoogle Scholar
  32. 32.
    Hirrlinger J, Dringen R. The cytosolic redox state of astrocytes: maintenance, regulation and functional implications for metabolite trafficking. Brain Res Rev. 2010;63:177–88.PubMedGoogle Scholar
  33. 33.
    Bryleva EY, Brundin L. Kynurenine pathway metabolites and suicidality. Neuropharmacology. 2017;112:324–30.PubMedGoogle Scholar
  34. 34.
    Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology. 2014;231:3663–76.PubMedGoogle Scholar
  35. 35.
    Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new “5-HT” hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35:702–21.Google Scholar
  36. 36.
    Bradley KAL, Case JAC, Khan O, Ricart T, Hanna A, Alonso CM, et al. The role of the kynurenine pathway in suicidality in adolescent major depressive disorder. Psychiatry Res. 2015;227:206–12.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Vikelis M, Mitsikostas DD. The role of glutamate and its receptors in migraine. CNS Neurol Disord Drug Targets. 2007;6:251–7.PubMedGoogle Scholar
  38. 38.
    Vécsei L, Majláth Z, Balog A, Tajti J. Drug targets of migraine and neuropathy: treatment of hyperexcitability. CNS Neurol Disord Drug Targets. 2015;14:664–76.PubMedGoogle Scholar
  39. 39.
    Sas K, Szabó E, Vécsei L. Mitochondria, oxidative stress and the kynurenine system, with a focus on ageing and neuroprotection. Molecules Basel Switz. 2018;23.PubMedCentralGoogle Scholar
  40. 40.
    Gasparini CF, Griffiths LR. The biology of the glutamatergic system and potential role in migraine. Int J Biomed Sci. 2013;9:1–8.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Behan WM, McDonald M, Darlington LG, Stone TW. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol. 1999;128:1754–60.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Tavares RG, Tasca CI, Santos CE, Wajner M, Souza DO, Dutra-Filho CS. Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain. Neuroreport. 2000;11:249–53.PubMedGoogle Scholar
  43. 43.
    Kemp JA, Foster AC, Leeson PD, Priestley T, Tridgett R, Iversen LL, et al. 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. Proc Natl Acad Sci U S A. 1988;85:6547–50.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Sas K, Robotka H, Rózsa E, Agoston M, Szénási G, Gigler G, et al. Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus. Neurobiol Dis. 2008;32:302–8.PubMedGoogle Scholar
  45. 45.
    Pompili M, Orsolini L, Lamis DA, Goldsmith DR, Nardella A, Falcone G, et al. Suicide prevention in schizophrenia: do long-acting injectable antipsychotics (LAIs) have a role? CNS Neurol Disord Drug Targets. 2017;16:454–62.PubMedGoogle Scholar
  46. 46.
    Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999;20:201–25.PubMedGoogle Scholar
  47. 47.
    Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006;1073–1074:25–37.PubMedGoogle Scholar
  48. 48.
    Stewart JC, Rand KL, Muldoon MF, Kamarck TW. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav Immun. 2009;23:936–44.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Zepf FD, Stewart RM, Guillemin G, Ruas JL. Inflammation, immunology, stress and depression: a role for kynurenine metabolism in physical exercise and skeletal muscle. Acta Neuropsychiatr. 2016;28:244–5.PubMedGoogle Scholar
  50. 50.
    Agudelo LZ, Femenía T, Orhan F, Porsmyr-Palmertz M, Goiny M, Martinez-Redondo V, et al. Skeletal muscle PGC-1α1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell. 2014;159:33–45.PubMedGoogle Scholar
  51. 51.
    Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health. Science. 2017;357.Google Scholar
  52. 52.
    Wirleitner B, Neurauter G, Schröcksnadel K, Frick B, Fuchs D. Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem. 2003;10:1581–91.PubMedGoogle Scholar
  53. 53.
    Musso T, Gusella GL, Brooks A, Longo DL, Varesio L. Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. Blood. 1994;83:1408–11.PubMedGoogle Scholar
  54. 54.
    Kanai M, Nakamura T, Funakoshi H. Identification and characterization of novel variants of the tryptophan 2,3-dioxygenase gene: differential regulation in the mouse nervous system during development. Neurosci Res. 2009;64:111–7.PubMedGoogle Scholar
  55. 55.
    Li J, Wang Y, Zhou R, Zhang H, Yang L, Wang B, et al. Association between tryptophan hydroxylase gene polymorphisms and attention deficit hyperactivity disorder in Chinese Han population. Am J Med Genet Part B Neuropsychiatr Genet. 2006;141B:126–9.Google Scholar
  56. 56.
    Li JS, Han Q, Fang J, Rizzi M, James AA, Li J. Biochemical mechanisms leading to tryptophan 2,3-dioxygenase activation. Arch Insect Biochem Physiol. 2007;64:74–87.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LMF, et al. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int Immunol. 2014;26:357–67.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Saito K, Crowley JS, Markey SP, Heyes MP. A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J Biol Chem. 1993;268:15496–503.PubMedGoogle Scholar
  59. 59.
    Bender DA. Biochemistry of tryptophan in health and disease. Mol Asp Med. 1983;6:101–97.Google Scholar
  60. 60.
    Salter M, Knowles RG, Pogson CI. Quantification of the importance of individual steps in the control of aromatic amino acid metabolism. Biochem J. 1986;234:635–47.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Holmes EW. Determination of serum kynurenine and hepatic tryptophan dioxygenase activity by high-performance liquid chromatography. Anal Biochem. 1988;172:518–25.PubMedGoogle Scholar
  62. 62.
    Takeuchi F, Tsubouchi R, Izuta S, Shibata Y. Kynurenine metabolism and xanthurenic acid formation in vitamin B6-deficient rat after tryptophan injection. J Nutr Sci Vitaminol (Tokyo). 1989;35:111–22.Google Scholar
  63. 63.
    Pawlak D, Tankiewicz A, Matys T, Buczko W. Peripheral distribution of kynurenine metabolites and activity of kynurenine pathway enzymes in renal failure. J Physiol Pharmacol. 2003;54:175–89.PubMedGoogle Scholar
  64. 64.
    Gál EM, Sherman AD. L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res. 1980;5:223–39.PubMedGoogle Scholar
  65. 65.
    Heyes MP, Chen CY, Major EO, Saito K. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J. 1997;326(Pt 2):351–6.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J. 1996;320(Pt 2):595–7.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther. 2002;303:1–10.PubMedGoogle Scholar
  68. 68.
    Bordelon YM, Chesselet MF, Nelson D, Welsh F, Erecińska M. Energetic dysfunction in quinolinic acid-lesioned rat striatum. J Neurochem. 1997;69:1629–39.PubMedGoogle Scholar
  69. 69.
    Santamaría A, Galván-Arzate S, Lisý V, Ali SF, Duhart HM, Osorio-Rico L, et al. Quinolinic acid induces oxidative stress in rat brain synaptosomes. Neuroreport. 2001;12:871–4.PubMedGoogle Scholar
  70. 70.
    Schwarcz R, Whetsell WO, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 1983;219:316–8.PubMedGoogle Scholar
  71. 71.
    Kim JP, Choi DW. Quinolinate neurotoxicity in cortical cell culture. Neuroscience. 1987;23:423–32.PubMedGoogle Scholar
  72. 72.
    Laugeray A, Launay J-M, Callebert J, Surget A, Belzung C, Barone PR. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res. 2010;210:84–91.PubMedGoogle Scholar
  73. 73.
    Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer’s disease hippocampus. Neuropathol Appl Neurobiol. 2005;31:395–404.PubMedGoogle Scholar
  74. 74.
    Guillemin GJ, Kerr SJ, Brew BJ. Involvement of quinolinic acid in AIDS dementia complex. Neurotox Res. 2005;7:103–23.PubMedGoogle Scholar
  75. 75.
    Moroni F, Russi P, Lombardi G, Beni M, Carlà V. Presence of kynurenic acid in the mammalian brain. J Neurochem. 1988;51:177–80.PubMedGoogle Scholar
  76. 76.
    Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev. 1993;45:309–79.Google Scholar
  77. 77.
    Stone TW, Addae JI. The pharmacological manipulation of glutamate receptors and neuroprotection. Eur J Pharmacol. 2002;447:285–96.PubMedGoogle Scholar
  78. 78.
    Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001;313:96–8.PubMedGoogle Scholar
  79. 79.
    Zanos P, Piantadosi SC, Wu H-Q, Pribut HJ, Dell MJ, Can A, et al. The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/glycineB-site inhibition. J Pharmacol Exp Ther. 2015;355:76–85.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Goldstein LE, Leopold MC, Huang X, Atwood CS, Saunders AJ, Hartshorn M, et al. 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry. 2000;39:7266–75.PubMedGoogle Scholar
  81. 81.
    Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001;50:521–30.PubMedGoogle Scholar
  82. 82.
    Sathyasaikumar KV, Stachowski EK, Wonodi I, Roberts RC, Rassoulpour A, McMahon RP, et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull. 2011;37:1147–56.PubMedGoogle Scholar
  83. 83.
    Linderholm KR, Skogh E, Olsson SK, Dahl M-L, Holtze M, Engberg G, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 2012;38:426–32.PubMedGoogle Scholar
  84. 84.
    Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindström LH, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res. 2005;80:315–22.PubMedGoogle Scholar
  85. 85.
    Johansson A-S, Owe-Larsson B, Asp L, Kocki T, Adler M, Hetta J, et al. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. J Psychiatr Res. 2013;47:1815–23.PubMedGoogle Scholar
  86. 86.
    Oxenkrug G, van der Hart M, Roeser J, Summergrad P. Anthranilic acid: a potential biomarker and treatment target for schizophrenia. Ann Psychiatry Ment Health. 2016;4.Google Scholar
  87. 87.
    Atlas A, Gisslén M, Nordin C, Lindström L, Schwieler L. Acute psychotic symptoms in HIV-1 infected patients are associated with increased levels of kynurenic acid in cerebrospinal fluid. Brain Behav Immun. 2007;21:86–91.PubMedGoogle Scholar
  88. 88.
    Ravikumar A, Deepadevi KV, Arun P, Manojkumar V, Kurup PA. Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. Neurol India. 2000;48:231–8.PubMedGoogle Scholar
  89. 89.
    Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991;56:2007–17.Google Scholar
  90. 90.
    Chang YF, Cauley RK, Chang JD, Rao VV. L-alpha-aminoadipate inhibits kynurenate synthesis in rat brain hippocampus and tissue culture. Neurochem Res. 1997;22:825–9.PubMedGoogle Scholar
  91. 91.
    Speciale C, Wu HQ, Cini M, Marconi M, Varasi M, Schwarcz R. (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur J Pharmacol. 1996;315:263–7.PubMedGoogle Scholar
  92. 92.
    Röver S, Cesura AM, Huguenin P, Kettler R, Szente A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem. 1997;40:4378–85.PubMedGoogle Scholar
  93. 93.
    Clunie M, Crone L-A, Klassen L, Yip R. Psychiatric side effects of indomethacin in parturients. Can J Anaesth. 2003;50:586–8.PubMedGoogle Scholar
  94. 94.
    Schwieler L, Erhardt S, Nilsson L, Linderholm K, Engberg G. Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons--possible involvement of endogenous kynurenic acid. Synapse. 2006;59:290–8.PubMedGoogle Scholar
  95. 95.
    Wonodi I, Stine OC, Sathyasaikumar KV, Roberts RC, Mitchell BD, Hong LE, et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry. 2011;68:665–74.PubMedGoogle Scholar
  96. 96.
    Sellgren CM, Kegel ME, Bergen SE, Ekman CJ, Olsson S, Larsson M, et al. A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. Mol Psychiatry. 2016;21:1342–50.PubMedGoogle Scholar
  97. 97.
    Karlsson H. Viruses and schizophrenia, connection or coincidence? Neuroreport. 2003;14:535–42.PubMedGoogle Scholar
  98. 98.
    Canetta SE, Brown AS. Prenatal infection, maternal immune activation, and risk for schizophrenia. Transl Neurosci. 2012;3:320–7.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis. 2004;15:618–29.PubMedGoogle Scholar
  100. 100.
    Asp L, Beraki S, Kristensson K, Ogren SO, Karlsson H. Neonatal infection with neurotropic influenza a virus affects working memory and expression of type III Nrg1 in adult mice. Brain Behav Immun. 2009;23:733–41.PubMedGoogle Scholar
  101. 101.
    Liu X-C, Holtze M, Powell SB, Terrando N, Larsson MK, Persson A, et al. Behavioral disturbances in adult mice following neonatal virus infection or kynurenine treatment--role of brain kynurenic acid. Brain Behav Immun. 2014;36:80–9.PubMedGoogle Scholar
  102. 102.
    Carlborg A, Winnerbäck K, Jönsson EG, Jokinen J, Nordström P. Suicide in schizophrenia. Expert Rev Neurother. 2010;10:1153–64.PubMedGoogle Scholar
  103. 103.
    Asberg M. Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies. Ann N Y Acad Sci. 1997;836:158–81.PubMedGoogle Scholar
  104. 104.
    Barrett TB, Hauger RL, Kennedy JL, Sadovnick AD, Remick RA, Keck PE, et al. Evidence that a single nucleotide polymorphism in the promoter of the G protein receptor kinase 3 gene is associated with bipolar disorder. Mol Psychiatry. 2003;8:546–57.PubMedGoogle Scholar
  105. 105.
    Barrett TB, Emberton JE, Nievergelt CM, Liang SG, Hauger RL, Eskin E, et al. Further evidence for association of GRK3 to bipolar disorder suggests a second disease mutation. Psychiatr Genet. 2007;17:315–22.PubMedGoogle Scholar
  106. 106.
    Askland K, Parsons M. Toward a biaxial model of “bipolar” affective disorders: spectrum phenotypes as the products of neuroelectrical and neurochemical alterations. J Affect Disord. 2006;94:15–33.PubMedGoogle Scholar
  107. 107.
    Anguelova M, Benkelfat C, Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective disorders. Mol Psychiatry. 2003;8:574–91.PubMedGoogle Scholar
  108. 108.
    Mahmood T, Silverstone T. Serotonin and bipolar disorder. J Affect Disord. 2001;66:1–11.Google Scholar
  109. 109.
    Serretti A, Lilli R, Lorenzi C, Lattuada E, Cusin C, Smeraldi E. Serotonin transporter gene (5-HTTLPR) and major psychoses. Mol Psychiatry. 2002;7:95–9.PubMedGoogle Scholar
  110. 110.
    Bellivier F, Henry C, Szöke A, Schürhoff F, Nosten-Bertrand M, Feingold J, et al. Serotonin transporter gene polymorphisms in patients with unipolar or bipolar depression. Neurosci Lett. 1998;255:143–6.PubMedGoogle Scholar
  111. 111.
    Hoekstra R, Fekkes D, Loonen AJM, Pepplinkhuizen L, Tuinier S, Verhoeven WMA. Bipolar mania and plasma amino acids: increased levels of glycine. Eur Neuropsychopharmacol. 2006;16:71–7.PubMedGoogle Scholar
  112. 112.
    Myint AM, Kim YK. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses. 2003;61:519–25.PubMedGoogle Scholar
  113. 113.
    Sheehan DV, Nakagome K, Asami Y, Pappadopulos EA, Boucher M. Restoring function in major depressive disorder: a systematic review. J Affect Disord. 2017;215:299–313.PubMedGoogle Scholar
  114. 114.
    Küster OC, Laptinskaya D, Fissler P, Schnack C, Zügel M, Nold V, et al. Novel blood-based biomarkers of cognition, stress, and physical or cognitive training in older adults at risk of dementia: preliminary evidence for a role of BDNF, irisin, and the kynurenine pathway. J Alzheimers Dis. 2017;59:1097–111.PubMedGoogle Scholar
  115. 115.
    Meier TB, Drevets WC, Teague TK, Wurfel BE, Mueller SC, Bodurka J, et al. Kynurenic acid is reduced in females and oral contraceptive users: implications for depression. Brain Behav Immun. 2018;67:59–64.PubMedGoogle Scholar
  116. 116.
    Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626–38.PubMedGoogle Scholar
  117. 117.
    Holsboer F. How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci. 2008;9:638–46.PubMedGoogle Scholar
  118. 118.
    Pearson SJ, Reynolds GP. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington’s disease. Neurosci Lett. 1992;144:199–201.PubMedGoogle Scholar
  119. 119.
    Haroon et al., 2012 - PubMed - NCBI [Internet]. [cited 2018 Aug 14]. Available from:
  120. 120.
    Maddison DC, Giorgini F. The kynurenine pathway and neurodegenerative disease. Semin Cell Dev Biol. 2015;40:134–41.PubMedGoogle Scholar
  121. 121.
    Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpé S, et al. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients. Brain Behav Immun. 2011;25:1576–81.PubMedGoogle Scholar
  122. 122.
    Sperner-Unterweger B, Kohl C, Fuchs D. Immune changes and neurotransmitters: possible interactions in depression? Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:268–76.Google Scholar
  123. 123.
    Jeon SW, Kim Y-K. Inflammation-induced depression: its pathophysiology and therapeutic implications. J Neuroimmunol. 2017;313:92–8.PubMedGoogle Scholar
  124. 124.
    Hashimoto K. Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci. 2015;16:7796–801.PubMedPubMedCentralGoogle Scholar
  125. 125.
    Zhang J-C, Yao W, Hashimoto K. Brain-derived neurotrophic factor (BDNF)-TrkB signaling in inflammation-related depression and potential therapeutic targets. Curr Neuropharmacol. 2016;14:721–31.PubMedPubMedCentralGoogle Scholar
  126. 126.
    Yang J-J, Wang N, Yang C, Shi J-Y, Yu H-Y, Hashimoto K. Serum interleukin-6 is a predictive biomarker for ketamine’s antidepressant effect in treatment-resistant patients with major depression. Biol Psychiatry. 2015;77:e19–20.PubMedGoogle Scholar
  127. 127.
    Burke TF, Advani T, Adachi M, Monteggia LM, Hensler JG. Sensitivity of hippocampal 5-HT1A receptors to mild stress in BDNF-deficient mice. Int J Neuropsychopharmacol. 2013;16:631–45.PubMedGoogle Scholar
  128. 128.
    Dugan AM, Parrott JM, Redus L, Hensler JG, O’Connor JC. Low-level stress induces production of neuroprotective factors in wild-type but not BDNF+/− mice: interleukin-10 and kynurenic acid. Int J Neuropsychopharmacol. 2015;19:pyv089.PubMedPubMedCentralGoogle Scholar
  129. 129.
    Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science. 2006;311:864–8.PubMedGoogle Scholar
  130. 130.
    Jin Y, Sumsuzzman DM, Choi J, Kang H, Lee S-R, Hong Y. Molecular and functional interaction of the myokine irisin with physical exercise and Alzheimer’s disease. Molecules Basel Switz. 2018;23.PubMedCentralGoogle Scholar
  131. 131.
    Wrann CD, White JP, Salogiannnis J, Laznik-Bogoslavski D, Wu J, Ma D, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013;18:649–59.PubMedPubMedCentralGoogle Scholar
  132. 132.
    Mancuso R, Hernis A, Agostini S, Rovaris M, Caputo D, Fuchs D, et al. Indoleamine 2,3 dioxygenase (IDO) expression and activity in relapsing-remitting multiple sclerosis. PLoS One. 2015;10:e0130715.PubMedPubMedCentralGoogle Scholar
  133. 133.
    Lovelace MD, Varney B, Sundaram G, Lennon MJ, Lim CK, Jacobs K, et al. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. Neuropharmacology. 2017;112:373–88.PubMedGoogle Scholar
  134. 134.
    Manoharan S, Guillemin GJ, Abiramasundari RS, Essa MM, Akbar M, Akbar MD. The role of reactive oxygen species in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease: a mini review. Oxidative Med Cell Longev. 2016;2016:8590578.Google Scholar
  135. 135.
    Vécsei L, Szalárdy L, Fülöp F, Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov. 2013;12:64–82.PubMedGoogle Scholar
  136. 136.
    Zwilling D, Huang S-Y, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu H-Q, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2011;145:863–74.PubMedPubMedCentralGoogle Scholar
  137. 137.
    Malinova TS, Dijkstra CD, de Vries HE. Serotonin: a mediator of the gut-brain axis in multiple sclerosis. Mult Scler. 2018;24:1144–50.PubMedGoogle Scholar
  138. 138.
    Anderson G, Rodriguez M. Multiple sclerosis, seizures, and antiepileptics: role of IL-18, IDO, and melatonin. Eur J Neurol. 2011;18:680–5.PubMedGoogle Scholar
  139. 139.
    Rozov SV, Filatova EV, Orlov AA, Volkova AV, Zhloba ARA, Blashko EL, et al. N1-acetyl-N2-formyl-5-methoxykynuramine is a product of melatonin oxidation in rats. J Pineal Res. 2003;35:245–50.PubMedGoogle Scholar
  140. 140.
    Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem. 2016;139(Suppl 1):318–24.Google Scholar
  141. 141.
    de Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5:525–35.PubMedGoogle Scholar
  142. 142.
    Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med. 1998;339:1044–53.PubMedGoogle Scholar
  143. 143.
    Ogawa T, Matson WR, Beal MF, Myers RH, Bird ED, Milbury P, et al. Kynurenine pathway abnormalities in Parkinson’s disease. Neurology. 1992;42:1702–6.PubMedGoogle Scholar
  144. 144.
    Chang K-H, Cheng M-L, Tang H-Y, Huang C-Y, Wu Y-R, Chen C-M. Alternations of metabolic profile and kynurenine metabolism in the plasma of Parkinson’s disease. Mol Neurobiol. 2018:1–10.Google Scholar
  145. 145.
    Jauch D, Urbańska EM, Guidetti P, Bird ED, Vonsattel JP, Whetsell WO, et al. Dysfunction of brain kynurenic acid metabolism in Huntington’s disease: focus on kynurenine aminotransferases. J Neurol Sci. 1995;130:39–47.PubMedGoogle Scholar
  146. 146.
    Havelund JF, Andersen AD, Binzer M, Blaabjerg M, Heegaard NHH, Stenager E, et al. Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia. J Neurochem. 2017;142:756–66.PubMedGoogle Scholar
  147. 147.
    Schwarcz R. Kynurenines and glutamate: multiple links and therapeutic implications. Adv Pharmacol. 2016;76:13–37.PubMedPubMedCentralGoogle Scholar
  148. 148.
    Schwarz MJ, Guillemin GJ, Teipel SJ, Buerger K, Hampel H. Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer’s disease patients from controls. Eur Arch Psychiatry Clin Neurosci. 2013;263:345–52.PubMedGoogle Scholar
  149. 149.
    Amori L, Wu H-Q, Marinozzi M, Pellicciari R, Guidetti P, Schwarcz R. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience. 2009;159:196–203.PubMedGoogle Scholar
  150. 150.
    Grégoire L, Rassoulpour A, Guidetti P, Samadi P, Bédard PJ, Izzo E, et al. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav Brain Res. 2008;186:161–7.PubMedGoogle Scholar
  151. 151.
    Lewitt PA, Li J, Lu M, Beach TG, Adler CH, Guo L, et al. 3-hydroxykynurenine and other Parkinson’s disease biomarkers discovered by metabolomic analysis. Mov Disord. 2013;28:1653–60.PubMedGoogle Scholar
  152. 152.
    Lim CK, Fernández-Gomez FJ, Braidy N, Estrada C, Costa C, Costa S, et al. Involvement of the kynurenine pathway in the pathogenesis of Parkinson’s disease. Prog Neurobiol. 2017;155:76–95.PubMedGoogle Scholar
  153. 153.
    Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Kynurenine pathway metabolism and the microbiota-gut-brain axis. Neuropharmacology. 2017;112:399–412.PubMedGoogle Scholar
  154. 154.
    Pláteník J, Stopka P, Vejrazka M, Stípek S. Quinolinic acid-iron(ii) complexes: slow autoxidation, but enhanced hydroxyl radical production in the Fenton reaction. Free Radic Res. 2001;34:445–59.PubMedGoogle Scholar
  155. 155.
    Gulaj E, Pawlak K, Bien B, Pawlak D. Kynurenine and its metabolites in Alzheimer’s disease patients. Adv Med Sci. 2010;55:204–11.PubMedGoogle Scholar
  156. 156.
    Ardura-Fabregat A, Boddeke EWGM, Boza-Serrano A, Brioschi S, Castro-Gomez S, Ceyzériat K, et al. Targeting neuroinflammation to treat Alzheimer’s disease. CNS Drugs. 2017;31:1057–82.PubMedPubMedCentralGoogle Scholar
  157. 157.
    Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res. 2009;16:77–86.PubMedGoogle Scholar
  158. 158.
    Ting KK, Brew BJ, Guillemin GJ. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer’s disease. J Neuroinflammation. 2009;6:36.PubMedPubMedCentralGoogle Scholar
  159. 159.
    Hartai Z, Juhász A, Rimanóczy A, Janáky T, Donkó T, Dux L, et al. Decreased serum and red blood cell kynurenic acid levels in Alzheimer’s disease. Neurochem Int. 2007;50:308–13.PubMedGoogle Scholar
  160. 160.
    Guillemin GJ, Smythe GA, Veas LA, Takikawa O, Brew BJ. A beta 1-42 induces production of quinolinic acid by human macrophages and microglia. Neuroreport. 2003;14:2311–5.PubMedGoogle Scholar
  161. 161.
    Walker DG, Link J, Lue L-F, Dalsing-Hernandez JE, Boyes BE. Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol. 2006;79:596–610.PubMedGoogle Scholar
  162. 162.
    Okuda S, Nishiyama N, Saito H, Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem. 1998;70:299–307.PubMedGoogle Scholar
  163. 163.
    Vazquez S, Aquilina JA, Jamie JF, Sheil MM, Truscott RJW. Novel protein modification by kynurenine in human lenses. J Biol Chem. 2002;277:4867–73.PubMedGoogle Scholar
  164. 164.
    Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One. 2009;4:e6344.PubMedPubMedCentralGoogle Scholar
  165. 165.
    Forrest CM, McNair K, Pisar M, Khalil OS, Darlington LG, Stone TW. Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine. Neuroscience. 2015;310:91–105.PubMedPubMedCentralGoogle Scholar
  166. 166.
    Schroecksnadel K, Winkler C, Fuith LC, Fuchs D. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett. 2005;223:323–9.PubMedGoogle Scholar
  167. 167.
    Schröcksnadel K, Widner B, Bergant A, Neurauter G, Schennach H, Schröcksnadel H, et al. Longitudinal study of tryptophan degradation during and after pregnancy. Life Sci. 2003;72:785–93.PubMedGoogle Scholar
  168. 168.
    Heyes MP, Saito K, Lackner A, Wiley CA, Achim CL, Markey SP. Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. FASEB J. 1998;12:881–96.PubMedGoogle Scholar
  169. 169.
    Huengsberg M, Winer JB, Gompels M, Round R, Ross J, Shahmanesh M. Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. Clin Chem. 1998;44:858–62.PubMedGoogle Scholar
  170. 170.
    Look MP, Altfeld M, Kreuzer KA, Riezler R, Stabler SP, Allen RH, et al. Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease. AIDS Res Hum Retrovir. 2000;16:1215–21.PubMedGoogle Scholar
  171. 171.
    Murr C, Gerlach D, Widner B, Dierich MP, Fuchs D. Neopterin production and tryptophan degradation in humans infected by Streptococcus pyogenes. Med Microbiol Immunol. 2001;189:161–3.PubMedGoogle Scholar
  172. 172.
    Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer. 2002;86:1691–6.PubMedPubMedCentralGoogle Scholar
  173. 173.
    Young SN, Joseph MH, Gauthier S. Studies on kynurenine in human cerebrospinal fluid: lowered levels in epilepsy. J Neural Transm. 1983;58:193–204.PubMedGoogle Scholar
  174. 174.
    Baig S, Halawa I, Qureshi GA. High performance liquid chromatography as a tool in the definition of abnormalities in monoamine and tryptophan metabolites in cerebrospinal fluid from patients with neurological disorders. Biomed Chromatogr. 1991;5:108–12.PubMedGoogle Scholar
  175. 175.
    Heyes MP, Saito K, Devinsky O, Nadi NS. Kynurenine pathway metabolites in cerebrospinal fluid and serum in complex partial seizures. Epilepsia. 1994;35:251–7.PubMedGoogle Scholar
  176. 176.
    Heyes MP, Saito K, Milstien S, Schiff SJ. Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children. J Neurol Sci. 1995;133:112–8.PubMedGoogle Scholar
  177. 177.
    Medana IM, Day NPJ, Salahifar-Sabet H, Stocker R, Smythe G, Bwanaisa L, et al. Metabolites of the kynurenine pathway of tryptophan metabolism in the cerebrospinal fluid of Malawian children with malaria. J Infect Dis. 2003;188:844–9.PubMedGoogle Scholar
  178. 178.
    Iłzecka J, Kocki T, Stelmasiak Z, Turski WA. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol Scand. 2003;107:412–8.PubMedGoogle Scholar
  179. 179.
    Theme 3 cognitive and psychological assessment and support. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(Suppl 1):81–92.Google Scholar
  180. 180.
    Rejdak K, Bartosik-Psujek H, Dobosz B, Kocki T, Grieb P, Giovannoni G, et al. Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci Lett. 2002;331:63–5.PubMedGoogle Scholar
  181. 181.
    Orlikov AB, Prakhye IB, Ryzov IV. Kynurenine in blood plasma and DST in patients with endogenous anxiety and endogenous depression. Biol Psychiatry. 1994;36:97–102.PubMedGoogle Scholar
  182. 182.
    Beal MF, Matson WR, Storey E, Milbury P, Ryan EA, Ogawa T, et al. Kynurenic acid concentrations are reduced in Huntington’s disease cerebral cortex. J Neurol Sci. 1992;108:80–7.PubMedGoogle Scholar
  183. 183.
    Sardar AM, Bell JE, Reynolds GP. Increased concentrations of the neurotoxin 3-hydroxykynurenine in the frontal cortex of HIV-1-positive patients. J Neurochem. 1995;64:932–5.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Abdulkarim Tutakhail
    • 1
    • 2
  • Lysiane Boulet
    • 3
  • Sarah Khabil
    • 1
  • Qand Agha Nazari
    • 2
  • Hafiza Hamid
    • 2
  • François Coudoré
    • 1
    Email author
  1. 1.CESP/National Institute of Health and Medical Research INSERM UMR-S 1178Paris-Sud University, Faculty of Pharmacy, Paris-Saclay UniversityOrsayFrance
  2. 2.Pharmacology Department, Faculty of PharmacyKabul UniversityKabulAfghanistan
  3. 3.Biochemistry DepartmentCentre Hospitalier Universitaire Grenoble-AlpesGrenobleFrance

Personalised recommendations